---
title: Genitourinary Symptoms With Levonorgestrel Releasing Intrauterine Systems
nct_id: NCT01730300
overall_status: COMPLETED
sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
study_type: OBSERVATIONAL
primary_condition: Lower Urinary Tract Symptoms
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01730300.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01730300"
ct_last_update_post_date: 2013-05-15
last_seen_at: "2026-05-12T06:32:27.213Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Genitourinary Symptoms With Levonorgestrel Releasing Intrauterine Systems

**Official Title:** Genitourinary Symptoms in Women Using Levonorgestrel Releasing Intrauterine Systems

**NCT ID:** [NCT01730300](https://clinicaltrials.gov/study/NCT01730300)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Bakirkoy Dr. Sadi Konuk Research and Training Hospital
- **Conditions:** Lower Urinary Tract Symptoms
- **Start Date:** 2012-06
- **Completion Date:** 2013-05
- **CT.gov Last Update:** 2013-05-15

## Brief Summary

The main purpose of the study was to evaluate the efficacy of Levonorgestrel Releasing Intrauterine devices (LNR-IUD) on genitourinary symptoms in patients with abnormal uterine bleeding. The patients were asked urogenital distress inventory (UDI) (which includes; irritative symptoms, stress symptoms, obstructive discomfort) and incontinence impact questionnaire (IIQ) (which includes; physical activity, travel, social/relationships, emotional health)questionnaires in the day of application LNR-IUD and six months later this procedure. Statistical analyse will be performed to evaluate the changes in this time period.

## Eligibility

- **Minimum age:** 15 Years
- **Maximum age:** 55 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* women using levonorgestrel releasing intrauterine device for the treatment of menorrhagia or adenomyosis

Exclusion Criteria:

* none
```

## Primary Outcomes

- **Urinary frequency** _(time frame: 6 months)_ — We think that the urinary frequency will be lesser after 6 months of the therapy.

## Secondary Outcomes

- **social activity** _(time frame: 6 months)_

## Locations (1)

- Bakirkoy Dr Sadi Konuk Teaching and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.bakirkoy dr sadi konuk teaching and research hospital, department of obstetrics and gynecology|istanbul||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01730300.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01730300*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*